18F-labelled fluorodeoxyglucose–positron emission tomography (FDG–PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma-Reference-Cited by-同舟云学术

18F-labelled fluorodeoxyglucose–positron emission tomography (FDG–PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma

Published:2013-01 Issue:2 Volume:49 Page:395-402
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Carlino Matteo S.,Saunders Catherine A.B.,Haydu Lauren E.,Menzies Alexander M.,Martin Curtis C.,Lebowitz Peter F.,Kefford Richard F.,Long Georgina V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis;Takata;Int J Cancer,2000

2. Intra- and inter-tumor heterogeneity of BRAF V600E mutations in primary and metastatic melanoma;Yancovitz;PLoS ONE,2012

3. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma;Katona;Am J Surg Pathol,2007

4. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression;Lin;Br J Cancer,2011

5. Intra-tumour heterogeneity: a looking glass for cancer?;Marusyk;Nat Rev Cancer,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review;Journal of Clinical Medicine;2024-09-12

2. An automated methodology for whole-body, multimodality tracking of individual cancer lesions;Physics in Medicine & Biology;2024-04-03

3. Single-cell RNA sequencing in melanoma: what have we learned so far?;eBioMedicine;2024-02

4. Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma;International Journal of Molecular Sciences;2024-01-31

5. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?;Clinical Nuclear Medicine;2023-12-19